Adjuvant chemotherapy after curative resection reduced the incidence of advanced adenomas by 85% in patients with low-risk stage II CRC.
Risk is reduced for individuals in the highest versus lowest healthy-eating quintile.
A meta-analysis indicates there's no need to decrease the interval between colonoscopies or other forms of screening.
The MEK inhibitor selumetinib does not appear to improve survival, contrary to prior findings.
Pembrolizumab induced complete remission in five of seven heavily pretreated and relapsed patients.
Adding bevacizumab to chemotherapy failed to improve 5-year overall survival.
Anticoagulation with enoxaparin significantly increased risk for major intracranial hemorrhage in patients with glioma.
Low response is associated with lack of platelet autoantibodies.
Expert hematopathology review and classification improved the accuracy of diagnosis and treatment planning.
Eculizumab can be discontinued despite continued complement activation.
Prof. Dr. med. Florian Otto
Tumor- und Brustzentrum ZeTuP, St. Gallen
E-Mail: E-Mail anzeigen
Immuntherapie ist in aller Munde. Checkpoint-Inhibitoren werden bei praktisch allen onkologischen Erkrankungen erprobt und erweisen sich häufig als wirksam – zumindest für eine gewisse Zeit. Aber wie entwickelt sich eine Resistenz? Dieser Frage sind Zaretsky und Kollegen im Kontext von vier Melanompatienten unter Pembrolizumab-Therapie nachgegangen und haben Defekte im Interferon-Signalweg sowie der Antigenpräsentation in den Tumorzellen gefunden.
Mortality was similar with active monitoring, prostatectomy, or radiotherapy during 10 years of follow-up.
Pregnant women with inherited thrombophilia have increased risk for VTE, independent of a family history of VTE.
The use of >12 serum tumor marker tests and/or 4 radiographic imaging tests per year provided no survival advantage.
Adding epirubicin to fluorouracil/platinum-based chemotherapy resulted in greater toxicity and no clear improvement in response.
Andexanet reduced anti–factor Xa activity and restored effective hemostasis in patients with major bleeding.
A 70-gene signature identified patients with high clinical risk and low molecular risk who achieved a 5-year survival rate of 94.7% without chemotherapy.
Declines in light chain levels were achieved in heavily pretreated patients.
The HER2-targeted combination regimen of trastuzumab and lapatinib may have activity in HER2-positive, chemotherapy-refractory disease.
Mutations preventing interferon-receptor signaling and antigen presentation are linked to acquired resistance.
Overall survival was significantly better with S-1 versus gemcitabine.